肠道菌群与结直肠癌发生发展息息相关，其中放线菌近年被发现具有“抗癌菌”作用，其机制与细胞凋亡内源性Bcl-2/Bax及外源性Fas/FasL信号通路有关。课题组前期临床研究发现祛邪胶囊相比安慰剂能显著提高晚期结直肠癌患者肠道放线菌分布比例，同时既往基础实验提示祛邪胶囊抗结直肠癌通过调控Bcl-2/Bax、Fas/FasL通路相关蛋白Bim、Cleaved-caspase 3等表达实现。然而祛邪胶囊是否通过调控放线菌介导上述细胞凋亡通路实现抗结直肠癌作用，目前尚不明确，这一问题对深入了解中药通过肠道菌群发挥抗癌作用的科学内涵具有重要创新意义。本课题计划通过体内及体外实验，观察祛邪胶囊对放线菌生长分布及代谢产物影响，验证体外、体内结直肠癌抑制效应，以细胞凋亡相关Bcl2/Bax、Fas/FasL通路为切入点，探讨其抗癌作用分子靶点及机理，可望让复杂的肠道菌群“为我所用”、成为抗癌利器。

Gut micro-biome is highly associated with carcinogenetic and development of colorectal cancer(CRC), in which Actinobacteria has been found to be a ‘cancer killer’ bacteria. And its anti tumor effect is related with exogenous and endogenous apoptosis Bcl-2/Bax and Fas/FasL pathway. Our previous clinical trial proved that Quxie capsule(QX) could significantly improved proportion of Actinobacteria for metastatic CRC patients. Basic research also revealed that QX could regulate Bcl-2/Bax and Fas/FasL related protein such as Bim and Cleaved-caspase 3 to suppress CRC. However, it is still not clear that whether the anti-CRC effect of QX is due to Actinobacteria modulated Bcl-2/Bax and Fas/FasL apoptosis. This scientific question is critical and innovative to further understand the mechanism of TCM herbal medicine anti-tumor effect by regulating micro-biome. Through vivo and vitro research, the current study aims to observe the impact of QX to Actinobacteria’s growth and distribution, as well as the level of its metabolites, and to reveal the anti-CRC effect of the interaction between QX and Actinobacteria. The study will also investigate the target and mechanism of such effect based on apoptosis Bcl-2/Bax and Fas/FasL singling pathway. We hope that our study could let gut micro-biome, though complicated, work for us and be used as strong weapon to eliminate cancer.